Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

ICON Bioscience

Status and phase: Completed; Phase 2

Conditions: Inflammation Associated With Cataract Surgery

Treatments: Drug: IBI-10090

Study type: Interventional

Funder types: Industry

Identifiers

NCT01606735

C11-01

Details and patient eligibility

About

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.

Enrollment: 172 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients scheduled for unilateral cataract surgery

Exclusion criteria

• Ocular, topical, or oral corticosteroids within 7 days of Day 0

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

172 participants in 3 patient groups

Dose 1

Experimental group

Treatment:

Drug: IBI-10090

Dose 2

Experimental group

Treatment:

Drug: IBI-10090

Dose 3

Experimental group

Treatment:

Drug: IBI-10090